Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2007

Ipsogen Accesses Affymetrix Microchip Technology for Development of IVD Tests

  • Affymetrix and Ipsogen signed a Powered by Affymetrix™ (PbA) agreement. With this transaction, Ipsogen gains nonexclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis.

    The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products. The resulting microarray-based tests will, the companies report, enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »